The update outlined nothing about future plans for PAT-SM6, so maybe a developer/partner is being sort to take it to the next stage, in exchange for upfront payments and royalties etc.and therefore follow the same path as PAT-SC1
So basically in the foreseeable future it all hinges on the details of the deal with Hefei Co-Source.
Remember that Patries bought PAT-SC1 from another company Debiopharm in the first place. Do we know if there are any financial arrangements with Debio about on selling SC1 to somebody else ?
Ann: Market Update, page-64
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.229M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $5.431K | 1.357M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 26519870 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 7889760 | 12 |
View Market Depth
| Last trade - 11.23am 15/11/2024 (20 minute delay) ? |
| PAB (ASX) Chart |